Literature DB >> 24976811

Cost-effectiveness and access to care in the treatment of hepatitis C virus infection.

Liesl Hagan1.   

Abstract

Entities:  

Year:  2014        PMID： 24976811      PMCID： PMC4073539     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.

Authors:  L M Hagan; Z Yang; M Ehteshami; R F Schinazi
Journal:  J Viral Hepat       Date:  2013-06-10       Impact factor: 3.728

2.  Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic.

Authors:  Lesley Miller; Shelly-Ann Fluker; Melissa Osborn; Xiaoxia Liu; Akilah Strawder
Journal:  J Natl Med Assoc       Date:  2012 May-Jun       Impact factor: 1.798

3.  The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.

Authors:  Phil McEwan; Thomas Ward; Yong Yuan; Ray Kim; Gilbert L'italien
Journal:  Hepatology       Date:  2013-05-27       Impact factor: 17.425

Review 4.  Treatment as prevention and cure towards global eradication of hepatitis C virus.

Authors:  Liesl M Hagan; Paul Root Wolpe; Raymond F Schinazi
Journal:  Trends Microbiol       Date:  2013-11-14       Impact factor: 17.079
  4 in total
  1 in total

1.  Injecting drug use opportunities and reasons for choosing not to inject: A population-based study of Australian young adults who use stimulants.

Authors:  Luke Edward Casey; Davoud Pourmarzi; Ellen Leslie Wessel; Robert Kemp; Andrew Smirnov
Journal:  Drug Alcohol Rev       Date:  2022-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.